目的:本研究通过回顾性分析晚期胃肠癌患者化疗后血红蛋白(Hb)水平与其临床疗效的关系,为临床治疗提供依据。方法:选择2009年1月~2014年12月我院收治的晚期胃肠癌患者共85例,采用回顾性调查方法,对患者进行1~5年的随访,分别对患者化疗前后贫血发生情况、Hb水平与临床疗效的关系、Hb水平与患者平均生存时间的关系进行分析。结果:化疗后患者发生贫血的比例(78.82%)明显高于化疗前(48.24%),差异有统计学意义(P<0.05);PR组和SD组患者化疗前后Hb值的差异无统计学意义(P>0.05);化疗前PD组患者Hb值显著高于化疗后,差异有统计学意义(P<0.05);Hb水平越高,患者的平均生存时间越长,Hb的水平和患者的生存时间呈正相关。结论:晚期胃肠癌患者化疗后贫血发生率增加,化疗后Hb水平的变化与患者的预后和生存时间均存在相关关系,对患者进行常规治疗的同时采取相应措施纠正患者贫血症状,有利于改善晚期胃肠癌患者的预后,延长患者的生存时间。 Objective: In this study, we retrospectively analyzed the relationship between hemoglobin (Hb) level after chemotherapy and its clinical efficacy in patients with advanced gastrointestinal cancer and provided the basis for clinical treatment. Methods: A total of 85 patients with advanced gastrointestinal cancer who were treated in our hospital from January 2009 to December 2014 were retrospectively investigated. The patients were followed up for 1 to 5 years. The incidence of anemia before and after chemotherapy, Hb levels and clinical efficacy, Hb level and the average survival time of patients were analyzed. Results: The proportion of patients with anemia after chemotherapy (78.82%) was significantly higher than that before chemotherapy (48.24%), the difference was statistically significant (P <0.05). There was no significant difference in Hb between before and after chemotherapy in PR group and SD group (P> 0.05). The Hb in patients with PD before chemotherapy was significantly higher than that after chemotherapy (P <0.05). The higher the Hb level, the longer the average survival time of patients, the level of Hb and the survival of patients Time is positively correlated. Conclusion: The incidence of anemia in patients with advanced gastrointestinal cancer is increased after chemotherapy. The change of Hb level after chemotherapy is related to the prognosis and survival time of patients with advanced gastrointestinal cancer. At the same time, the routine treatment of patients should take appropriate measures to correct the symptoms of anemia, The prognosis of patients with advanced gastrointestinal cancer, to extend the survival time of patients.